# A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers

> **NCT05116865** · PHASE1 · COMPLETED · sponsor: **Huahui Health** · enrollment: 52 (actual)

## Conditions studied

- COVID-19 Respiratory Infection

## Interventions

- **BIOLOGICAL:** HH-120 Dose 1
- **BIOLOGICAL:** HH-120 Dose 2
- **BIOLOGICAL:** HH-120 Dose 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05116865
- **Lead sponsor:** Huahui Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2022-05-26
- **Final completion:** 2022-08-02
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116865, "A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05116865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*